Current Management of In-Stent Restenosis

被引:7
作者
Giacoppo, Daniele [1 ]
Mazzone, Placido Maria [1 ]
Capodanno, Davide [1 ]
机构
[1] Univ Catania, Dept Surg & Med Surg Specialties, Div Cardiol, Azienda Osped Univ Policlin Rodol San Marco, Via Santa Sofia 78, I-95124 Catania, Italy
关键词
in-stent restenosis; percutaneous coronary intervention; drug-coated balloon; drug-eluting stent; intravascular imaging; DRUG-ELUTING STENT; PACLITAXEL-COATED BALLOON; OPTICAL COHERENCE TOMOGRAPHY; DUAL-ANTIPLATELET THERAPY; PERCUTANEOUS CORONARY INTERVENTION; BIORESORBABLE VASCULAR SCAFFOLDS; RANDOMIZED-TRIAL; INTRAVASCULAR LITHOTRIPSY; CUTTING BALLOON; ARTERY-DISEASE;
D O I
10.3390/jcm13082377
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In-stent restenosis (ISR) remains the primary cause of target lesion failure following percutaneous coronary intervention (PCI), resulting in 10-year incidences of target lesion revascularization at a rate of approximately 20%. The treatment of ISR is challenging due to its inherent propensity for recurrence and varying susceptibility to available strategies, influenced by a complex interplay between clinical and lesion-specific conditions. Given the multiple mechanisms contributing to the development of ISR, proper identification of the underlying substrate, especially by using intravascular imaging, becomes pivotal as it can indicate distinct therapeutic requirements. Among standalone treatments, drug-coated balloon (DCB) angioplasty and drug-eluting stent (DES) implantation have been the most effective. The main advantage of a DCB-based approach is the avoidance of an additional metallic layer, which may otherwise enhance neointimal hyperplasia, provide the substratum for developing neoatherosclerosis, and expose the patient to a persistently higher risk of coronary ischemic events. On the other hand, target vessel scaffolding by DES implantation confers relevant mechanical advantages over DCB angioplasty, generally resulting in larger luminal gain, while drug elution from the stent surface ensures the inhibition of neointimal hyperplasia. Nevertheless, repeat stenting with DES also implies an additional permanent metallic layer that may reiterate and promote the mechanisms leading to ISR. Against this background, the selection of either DCB or DES on a patient- and lesion-specific basis as well as the implementation of adjuvant treatments, including cutting/scoring balloons, intravascular lithotripsy, and rotational atherectomy, hold the potential to improve the effectiveness of ISR treatment over time. In this review, we comprehensively assessed the available evidence from randomized trials to define contemporary interventional treatment of ISR and provide insights for future directions.
引用
收藏
页数:22
相关论文
共 136 条
[1]   Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial [J].
Adriaenssens, Tom ;
Dens, Jo ;
Ughi, Giovanni ;
Bennett, Johan ;
Dubois, Christophe ;
Sinnaeve, Peter ;
Wiyono, Stefanus ;
Coosemans, Mark ;
Belmans, Ann ;
D'hooge, Jan ;
Vrolix, Mathias ;
Desmet, Walter .
EUROINTERVENTION, 2014, 10 (04) :439-448
[2]   PCSK9 inhibitors: current status and emerging frontiers in lipid control [J].
Agnello, Federica ;
Mauro, Maria Sara ;
Rochira, Carla ;
Landolina, Davide ;
Finocchiaro, Simone ;
Greco, Antonio ;
Ammirabile, Nicola ;
Raffo, Carmelo ;
Mazzone, Placido Maria ;
Spagnolo, Marco ;
Occhipinti, Giovanni ;
Imbesi, Antonino ;
Giacoppo, Daniele ;
Capodanno, Davide .
EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2024, 22 (1-3) :41-58
[3]   Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis - Results of the Restenosis Cutting Balloon Evaluation Trial (RESCUT) [J].
Albiero, R ;
Silber, S ;
Di Mario, C ;
Cernigliaro, C ;
Battaglia, S ;
Reimers, B ;
Frasheri, A ;
Klauss, V ;
Auge, JM ;
Rubartelli, P ;
Morice, MC ;
Cremonesi, A ;
Schofer, J ;
Bortone, A ;
Colombo, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (06) :943-949
[4]   Management of in-stent restenosis [J].
Alfonso, Fernando ;
Coughlan, J. J. ;
Giacoppo, Daniele ;
Kastrati, Adnan ;
Byrne, Robert A. .
EUROINTERVENTION, 2022, 18 (02) :E103-U33
[5]   A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis -: Results of the restenosis intrastent:: Balloon angioplasty versus elective sirolimus-eluting stenting (RIBS-II) trial [J].
Alfonso, Fernando ;
Perez-Vizcayno, Maria-Jose ;
Hernandez, Rosana ;
Bethencourt, Armando ;
Marti, Vicens ;
Lopez-Minguez, Jose R. ;
Angel, Juan ;
Mantilla, Ramon ;
Moris, Cesar ;
Cequier, Angel ;
Sabate, Manel ;
Escaned, Javier ;
Moreno, Raul ;
Bañuelos, Camino ;
Suarez, Alfonso ;
Macaya, Carlos .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (11) :2152-2160
[6]   3-Year Clinical Follow-Up of the RIBS IV Clinical Trial A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents [J].
Alfonso, Fernando ;
Jose Perez-Vizcayno, Maria ;
Cuesta, Javier ;
Garcia del Blanco, Bruno ;
Garcia-Touchard, Arturo ;
Ramon Lopez-Minguez, Jose ;
Masotti, Monica ;
Zueco, Javier ;
Cequier, Angel ;
Velazquez, Maite ;
Moreno, Raul ;
Mainar, Vicente ;
Dominguez, Antonio ;
Moris, Cesar ;
Molina, Eduardo ;
Rivero, Fernando ;
Jimenez-Quevedo, Pilar ;
Gonzalo, Nieves ;
Fernandez-Perez, Cristina .
JACC-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (10) :981-991
[7]   Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis The RIBS VI Study [J].
Alfonso, Fernando ;
Cuesta, Javier ;
Jose Perez-Vizcayno, Maria ;
Garcia del Blanco, Bruno ;
Ramon Rumoroso, Jose ;
Bosa, Francisco ;
Perez de Prado, Armando ;
Masotti, Monica ;
Moreno, Raul ;
Cequier, Angel ;
Gutierrez, Hipolito ;
Garcia Touchard, Arturo ;
Ramon Lopez-Minguez, Jose ;
Zueco, Javier ;
Marti, Vicens ;
Velazquez, Maite ;
Moris, Cesar ;
Bastante, Teresa ;
Garcia-Guimaraes, Marcos ;
Rivero, Fernando ;
Fernandez, Cristina .
JACC-CARDIOVASCULAR INTERVENTIONS, 2017, 10 (18) :1841-1851
[8]   A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents The RIBS IV Randomized Clinical Trial [J].
Alfonso, Fernando ;
Perez-Vizcayno, Maria Jose ;
Cardenas, Alberto ;
del Blanco, Bruno Garcia ;
Garcia-Touchard, Arturo ;
Lopez-Minguez, Jose Ramon ;
Benedicto, Amparo ;
Masotti, Monica ;
Zueco, Javier ;
Iniguez, Andres ;
Velazquez, Maite ;
Moreno, Raul ;
Mainar, Vicente ;
Dominguez, Antonio ;
Pomar, Francisco ;
Melgares, Rafael ;
Rivero, Fernando ;
Jimenez-Quevedo, Pilar ;
Gonzalo, Nieves ;
Fernandez, Cristina ;
Macaya, Carlos .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (01) :23-33
[9]   Current Treatment of In-Stent Restenosis [J].
Alfonso, Fernando ;
Byrne, Robert A. ;
Rivero, Fernando ;
Kastrati, Adnan .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (24) :2659-2673
[10]   Treatment of Coronary In-Stent Restenosis With Bioabsorbable Vascular Scaffolds [J].
Alfonso, Fernando ;
Nuccio, Julio ;
Cuevas, Cecilia ;
Cardenas, Alberto ;
Gonzalo, Nieves ;
Jimenez-Quevedo, Pilar .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (25) :2875-2875